Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
- Viatris to Discontinue Nesp Biosimilar after Global Business Sell-Off
September 19, 2024
- Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
September 19, 2024
- Nippon Shinyaku Set to Expand Capricor DMD Therapy Pact to Europe
September 19, 2024
- AnGes’s Gene Therapy Collategene Gets FDA Breakthrough Therapy Tag
September 19, 2024
- Pfizer to Roll Out JN.1-Adapted COVID Vaccine
September 19, 2024
- J-TEC Prepping to File for Allogeneic Cultured Epidermis, Eyes Overseas Export
September 19, 2024
- Enhertu Effective in HER2 Breast Cancer with Brain Metastases
September 18, 2024
- Daiichi Sankyo’s HER3 ADC Hits PFS Goal in EGFR-Mutant Lung Cancer
September 18, 2024
- Lenvima/Keytruda Added to TACE Extend PFS in HCC
September 18, 2024
- Kissei’s Fibroid Drug Linzagolix Hits German Market
September 18, 2024
- GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
- Sandoz Now Distributor of FKB’s Humira Biosimilar in Japan
September 18, 2024
- MSD Files Belzutifan for von Hippel-Lindau Disease in Japan
September 18, 2024
- Japan’s 1st Tick-Borne Encephalitis Vaccine Now Available: Pfizer
September 17, 2024
- Taisho Seeks Japan Nod for Insomnia Med Vornorexant
September 13, 2024
- Opdivo-Yervoy Filed for 1st Line Use in MSI-H Colorectal Cancer in Japan
September 13, 2024
- Eisai Set on Streamlining Operations to Drive Drug Innovation: COO
September 13, 2024
- IBM, Kobe Biomedical Cluster Join Hands to Expedite Clinical Trials with AI
September 12, 2024
- Oral COVID Drugs Prescribed to 180,000 Patients: August Data
September 12, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…